Last Updated : April 25, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Spinraza | nusinersen | Spinal Muscular Atrophy | Do not reimburse | Complete | ||
| Spiriva Respimat | Tiotropium bromide | Chronic obstructive pulmonary disease | List with clinical criteria and/or conditions | Complete | ||
| Spravato | esketamine hydrochloride | Major depressive disorder (MDD), adults | Do not reimburse | Complete | ||
| Spriafil | Posaconazole | Aspergillus and Candida infections | Do not list | Complete | ||
| Stalevo | Carbidopa, levodopa and entacapone | Parkinsons Disease | List in a similar manner | Complete | ||
| Steglatro | ertugliflozin | Diabetes mellitus, Type 2 | Do not reimburse | Complete | ||
| Stelara | Ustekinumab | Arthritis, psoriatic | Do not list at the submitted price | Complete | ||
| Stelara | Ustekinumab | Psoriasis | List with clinical criteria and/or conditions | Complete | ||
| Stelara/Stelara I.V | ustekinumab | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Stelara/Stelara I.V. | ustekinumab | Crohn’s disease | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 25, 2024